In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy

This publication has 23 references indexed in Scilit:

• Gene therapy for ocular angiogenesis
  Clinical Science, 2003
• Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1–3 of angiostatin reduce retinal neovascularization
  Proceedings of the National Academy of Sciences, 2002
• Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1
  Gene Therapy, 2002
• Systemic Delivery of Antiangiogenic Adenovirus AdmATF Induces Liver Resistance to Metastasis and Prolongs Survival of Mice
  Human Gene Therapy, 1999
• Cloning, Expression, andin VitroActivity of Human Endostatin
  Biochemical and Biophysical Research Communications, 1999
• Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
  Gene Therapy, 1998
• Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
  Cell, 1997
• The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.
  Molecular Biology of the Cell, 1993
• Directed Plasminogen Activation at the Surface of Normal and Malignant Cells
  Published by Elsevier ,1991
• Blindness Caused by Diabetic Retinopathy
  American Journal of Ophthalmology, 1974